What is Histo-Path?
Established in 1974, Histo-Path Technical Specialties has cultivated a robust reputation for excellence in histopathology, providing critical diagnostic evaluation and consultation services. The company serves a diverse clientele, including dermatologists, gastroenterologists, and research institutions, by offering specialized immunohistochemistry and high-fidelity digital slide imaging. By maintaining a commitment to precision and rapid turnaround times, Histo-Path has solidified its position as a premium provider in the pathology landscape, effectively bridging the gap between traditional laboratory techniques and modern digital diagnostic requirements.
How much funding has Histo-Path raised?
Histo-Path has raised a total of $108K across 1 funding round:
Debt
$108K
Debt (2021): $108K with participation from PPP
Key Investors in Histo-Path
PPP
Public-Private Partnership
What's next for Histo-Path?
The recent capital injection serves as a catalyst for Histo-Path to scale its digital pathology capabilities and enhance its nationwide logistics network. As the company transitions into this next phase of growth, the focus will likely shift toward integrating advanced artificial intelligence tools for slide analysis and expanding its footprint in the research and coroner sectors. By leveraging this investment, Histo-Path aims to maintain its competitive edge, ensuring that its diagnostic solutions remain at the forefront of medical technology while continuing to meet the rigorous demands of its clinical partners.
See full Histo-Path company page
